Michael Payette, MD, MBA, FAAD

Closing out the series, each panelist names the combination of therapies they return to most often and delivers a final word on treating HS without hesitation.

An oral JAK inhibitor, a BTK inhibitor, and GLP-1 receptor agonists are reshaping what's possible in HS. The panel previews mechanisms it expects to reach patients next.

Ultrasound findings suggest inflammation is often present long before it's visible. The panel discusses what it takes for clinicians to treat HS with the same urgency as acne scarring.

With draining tunnels already present, the panel explains why mechanism of action matters, and why every groin exam should also be screening for Crohn's disease.

Twelve years of inconsistent care have left this patient reluctant to even be in the room. The panel sets short- and long-term goals for HS.

Choosing between TNF and IL-17 inhibition is only part of the picture. The panel maps out comorbidity screening, pain management, and where cannabis fits in.

This patient hasn't reached Hurley Stage 3, but her quality of life already has. The panel makes the case for escalating therapy well before anatomic damage sets in.

A five-year history of 'ingrown hairs' turns out to be HS. The panel explores why primary care so often misses this diagnosis, and how to rebuild trust once it's finally named.

New IL-17 inhibitors are changing first-line choices for adolescent and adult HS alike. The panel weighs efficacy benchmarks against follow-up strategy and comorbidity screening.

Parents often hear 'biologic' and imagine the worst. The panel explains how they build trust, set expectations, and time that first injection.

Examining a teenager's groin or axilla requires more than clinical skill. The panel discusses consent, comfort, and why HS diagnosis still lags for years.

A 17-year-old with painful, recurrent nodules has quietly given up gym class, social events, and her school prom. The panel walks through what her case demands.

Hurley staging built the field's first common language for HS, but the panel explains why it falls short and what newer scoring tools capture instead.

A decade after the first dedicated therapy arrived, the panel reflects on how far HS recognition and treatment have come, and how far they still need to go.

An expert in dermatology shares his insights into the management considerations with traditionally utilized treatments for generalized pustular psoriasis and discusses the impact of a recent approval in this space.

Dr Michael Payette discusses the patient QoL impacts and burden of generalized pustular psoriasis.

Michael Payette, MD, MBA, FAAD provides an overview of generalized pustular psoriasis, highlighting the challenges in the diagnosis of patients with this condition.